U.S. Congress has approved a temporary delay of sweeping new federal restrictions on hemp-derived THC and other cannabinoid products, sending the legislation to President Donald Trump after an unexpectedly lopsided House vote. On September 1, 2026, the House voted 370-48 to accept the Senate amendments to H.R. 6500, the Continuing Appropriations and Extensions Act, 2027. The Senate had already approved the measure 90-6 in August, meaning presidential action is now the final step required for the delay to become law.
For the hemp industry, the important provision is Section 2019. If Trump signs the bill as expected, most of the restrictive federal hemp definition scheduled to take effect November 12, 2026 will instead be postponed until December 11, 2026. The extension lasts only about four weeks and does not repeal the underlying law. But it gives lawmakers, regulators and businesses another month to determine whether Congress will replace what amounts to a broad prohibition on many current hemp cannabinoid products with a permanent federal regulatory system. The White House has formally endorsed H.R. 6500 and said President Trump’s senior advisers would recommend that he sign it.
The House Passed the Delay by an Overwhelming Margin
The final vote was far more bipartisan than the increasingly contentious hemp debate might have suggested. According to the House Clerk, 193 Republicans, 176 Democrats and one independent voted for H.R. 6500, while 19 Republicans and 29 Democrats opposed it. Because leadership brought the Senate amendments to the floor under suspension of the rules, approval required a two-thirds majority. The 370 affirmative votes cleared that threshold comfortably.
Hemp was only one component of a much larger bill. H.R. 6500 keeps the federal government funded through December 11, giving Congress additional time to complete fiscal 2027 appropriations and avoiding a shutdown at the end of September. That broader purpose helped produce the large bipartisan vote even as some House Republicans strongly objected to extending the hemp deadline. House Appropriations Committee Chairman Tom Cole confirmed after passage that the measure was being sent to Trump’s desk. Reuters likewise reported the 370-48 vote and the legislation’s completion of congressional action.
What Section 2019 Actually Does
The statutory language is unusually important because describing the provision simply as “delaying the hemp ban” misses a significant exception. Section 2019 says that until December 11, the amendments Congress enacted in Section 781 of Public Law 119-37 will apply only to two categories of products containing cannabinoids that are not capable of being naturally produced by Cannabis sativa. In other words, the federal crackdown on certain entirely non-naturally-occurring cannabinoids can still begin November 12, while most other changes to the definition of hemp are temporarily held back.
This means the existing federal hemp framework should generally continue for another month for naturally occurring cannabinoids and many products made from them, assuming they otherwise comply with federal and state law. Importantly, the delay also temporarily holds back the new restrictions on cannabinoids that can occur naturally in cannabis but have been synthesized or manufactured outside the plant. Those products are treated differently from cannabinoids that cannot occur naturally at all. Unless Congress acts again, the full set of Section 781 amendments is scheduled to take effect December 11.
The Underlying Law Would Dramatically Narrow the Definition of Hemp
The controversy began with legislation President Trump signed on November 12, 2025. Section 781 of Public Law 119-37 rewrote the federal hemp definition created by the 2018 Farm Bill. Under current law, hemp is generally distinguished from marijuana by a concentration of no more than 0.3 percent delta-9 THC on a dry-weight basis. The future definition instead uses total tetrahydrocannabinols, explicitly including THCA, and establishes additional restrictions for intermediate and finished cannabinoid products.
The most disruptive provision for consumer products is a limit of 0.4 milligrams combined total per container of total THC plus other cannabinoids determined to have, or be marketed as having, THC-like effects. That is 0.4 milligrams for the entire retail container—not 0.4 milligrams per serving. A beverage containing 5 milligrams of hemp-derived delta-9 THC, a package of gummies containing 50 milligrams, or a bottle of full-spectrum CBD containing a few milligrams of naturally occurring THC over dozens of servings could therefore exceed the new federal threshold by a wide margin.
The Coming Restrictions Reach Beyond Delta-8 Gummies
Much of the political discussion has focused on intoxicating products such as delta-8 THC gummies and hemp-derived delta-9 drinks sold outside state-licensed marijuana systems. Those products emerged after the 2018 Farm Bill removed qualifying hemp and hemp derivatives from the Controlled Substances Act’s marijuana definition. Manufacturers subsequently developed a national market for cannabinoid products that could contain intoxicating quantities while still meeting the Farm Bill’s dry-weight delta-9 THC requirement. The 2025 legislation was Congress’s attempt to close that gap.
But Congress wrote the 0.4-milligram provision broadly enough to affect some non-intoxicating full-spectrum CBD products as well. The Trump administration itself has acknowledged this issue. In a December 2025 executive order on cannabis and CBD research, the White House stated that some full-spectrum CBD products would become controlled as marijuana once Section 781 took effect because their THC content exceeded the per-container limit. Trump therefore directed administration officials to work with Congress on an updated definition that would preserve access to “appropriate full-spectrum CBD products” while restricting products posing serious health risks.
Trump Is Expected to Sign the Bill
As of the morning of September 2, the bill had cleared Congress and was awaiting presidential action. There is little reason to expect a veto. The Office of Management and Budget issued a formal Statement of Administration Policy on August 3 saying the administration supports the Senate amendment to H.R. 6500 and that Trump’s senior advisers would recommend signature if the legislation reached him in that form. The House passed exactly those Senate amendments.
The administration’s support also fits its broader cannabis policy. Trump’s December executive order specifically instructed White House officials to work with Congress on a regulatory structure for hemp-derived cannabinoid products, including possible limits on THC per serving, consideration of per-container limits and CBD-to-THC ratios. That is substantially different from treating 0.4 milligrams per container as the final answer for every consumer cannabinoid product. The one-month delay gives that regulatory effort additional time, although it does not guarantee Congress will reach an agreement before December.
The Senate Already Defeated an Attempt to Remove the Delay
The delay survived a direct challenge in the Senate. Sen. Ted Budd introduced Amendment 6747 specifically to strike Section 2019 from the funding legislation, which would have left the November 12 implementation date intact. Senators voted 61-32 to table Budd’s amendment, preserving the delay. The Senate then passed the overall continuing resolution by a much larger 90-6 vote.
Opposition extends beyond Congress. A bipartisan coalition of 35 state and territorial attorneys general urged lawmakers in August to reject efforts to delay or weaken the new hemp definition. The coalition argued that the 2018 framework allowed intoxicating cannabinoid products to proliferate in convenience stores, smoke shops and other venues without consistent age restrictions or product-safety standards. California Attorney General Rob Bonta and officials from states including Illinois, New Mexico and Connecticut joined the effort.
The Debate Is Increasingly Regulation Versus Prohibition
What makes the current development particularly important is that many opponents of the December restrictions are not arguing for a return to an entirely unregulated hemp market. Several competing bills would instead establish explicit federal rules covering cannabinoid manufacturing, testing, labeling, potency and age restrictions. One of the most substantial is the bipartisan Lawful Hemp Protection Act, H.R. 9830, introduced in July by Reps. Andy Barr and Angie Craig. Its stated purpose is to preserve lawful hemp commerce while protecting consumers from high-THC synthetic intoxicants.
Another proposal, the bipartisan Hemp Enforcement, Modernization, and Protection Act, H.R. 7212, would amend the Federal Food, Drug, and Cosmetic Act to establish federal regulation of cannabinoid hemp products. Separately, the Hemp Planting Predictability Act introduced in both chambers would replace Section 781’s one-year transition period with three years, effectively moving implementation into 2028 rather than merely adding one month. None of those bills has yet displaced the underlying 2025 restrictions, but their existence demonstrates that Congress has several potential paths besides simply allowing the 0.4-milligram standard to take effect.
One Month Is a Reprieve, Not a Resolution
For hemp companies, the most important practical point is that congressional passage of H.R. 6500 does not erase the coming federal restrictions. Assuming Trump signs it, businesses gain roughly four additional weeks. December 11 becomes the new major deadline for most of Section 781. Companies manufacturing products containing cannabinoids that cannot naturally occur in cannabis do not receive the same reprieve; the statutory carve-out allows those provisions to begin November 12.
The short duration makes the next stage of congressional negotiations unusually consequential. A manufacturer cannot easily redesign product formulations, packaging, laboratory testing, distribution contracts and inventory around a regulatory system that could change again within weeks. Hemp farmers and CBD companies face their own uncertainty because the forthcoming definition affects not only intoxicating retail products but aspects of the cannabinoid supply chain and total-THC testing. Lawmakers could pass comprehensive regulations, enact a longer delay or do nothing and allow the December deadline to arrive. Bloomberg Government described the congressional action as giving the industry additional time to fight the impending crackdown rather than eliminating it.
Congress Has Now Shifted the Hemp Fight to December
The September 1 vote represents a meaningful victory for hemp businesses and lawmakers who have argued that Congress should regulate cannabinoid products rather than abruptly remove most of them from the federally lawful hemp category. It also shows that the issue does not fall neatly along party lines. Nearly 200 House Republicans and more than 170 Democrats supported the broader bill containing the delay, while bipartisan lawmakers are sponsoring competing approaches to long-term hemp policy.
Yet the federal status of hemp-derived THC remains unresolved. Congress has changed the date, not settled the policy. If President Trump signs H.R. 6500, most hemp-derived cannabinoid products that would have faced the new restrictions on November 12 receive a temporary extension until December 11. During that window, lawmakers will have to decide whether the future of federally lawful hemp is built around a 0.4-milligram-per-container ceiling or around a more conventional regulatory model involving age limits, testing, potency standards and transparent labeling. For an industry created by Congress through the 2018 Farm Bill and then dramatically restricted by Congress seven years later, the next few months may determine what remains of the national hemp cannabinoid market.
